Delcath falls on longer-than-expected NDA review

Delcath Systems Inc. (NASDAQ:DCTH) fell $0.39 (19%) to $1.70 on Monday after FDA did not grant the company's request for Priority Review of an NDA for its chemosaturation system delivering melphalan t...